moxonidine has been researched along with Kidney Failure, Chronic in 9 studies
moxonidine: structure given in first source
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "End-stage renal disease (ESRD) is characterized by markedly increased sympathetic outflow that contributes to increased cardiovascular mortality in these patients." | 2.75 | Effects of moxonidine on sympathetic nerve activity in patients with end-stage renal disease. ( Hausberg, M; Krämer, BK; Pavenstädt, H; Rump, LC; Tokmak, F, 2010) |
| "Systemic hypertension often accompanies chronic renal failure and can accelerate its progression to end-stage renal disease (ESRD)." | 2.73 | Adjunctive treatment with moxonidine versus nitrendipine for hypertensive patients with advanced renal failure: a cost-effectiveness analysis. ( Baum, D; Greiner, W; Littlewood, KJ; Zoellner, Y, 2007) |
| "3mg once daily for 7 days and both pharmacokinetic and pharmacodynamic data were determined." | 1.27 | The influence of renal function on clinical pharmacokinetics of moxonidine. ( Hutt, HJ; Kirch, W; Plänitz, V, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hausberg, M | 1 |
| Tokmak, F | 1 |
| Pavenstädt, H | 1 |
| Krämer, BK | 1 |
| Rump, LC | 3 |
| Vonend, O | 2 |
| Marsalek, P | 1 |
| Russ, H | 1 |
| Wulkow, R | 1 |
| Oberhauser, V | 1 |
| Apel, T | 1 |
| Amann, K | 3 |
| Sellin, L | 1 |
| Stegbauer, J | 1 |
| Ritz, E | 3 |
| Neumann, J | 1 |
| Ligtenberg, G | 1 |
| Oey, L | 1 |
| Koomans, HA | 1 |
| Blankestijn, PJ | 1 |
| Kotanko, P | 1 |
| Littlewood, KJ | 1 |
| Greiner, W | 1 |
| Baum, D | 1 |
| Zoellner, Y | 1 |
| Nichols, C | 2 |
| Tornig, J | 2 |
| Schwarz, U | 1 |
| Zeier, M | 2 |
| Mall, G | 2 |
| Kirch, W | 1 |
| Hutt, HJ | 1 |
| Plänitz, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Renal Denervation on Blood Pressure in Patients With Chronic Kidney Disease and Uncontrolled Hypertension[NCT04264403] | 44 participants (Actual) | Interventional | 2020-01-23 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for moxonidine and Kidney Failure, Chronic
| Article | Year |
|---|---|
Cause and consequences of sympathetic hyperactivity in chronic kidney disease.
Topics: Adrenergic alpha-Agonists; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Arginine; Brain | 2006 |
4 trials available for moxonidine and Kidney Failure, Chronic
| Article | Year |
|---|---|
Effects of moxonidine on sympathetic nerve activity in patients with end-stage renal disease.
Topics: Adult; Female; Hemodynamics; Humans; Imidazoles; Kidney Failure, Chronic; Male; Middle Aged; Renal D | 2010 |
Moxonidine treatment of hypertensive patients with advanced renal failure.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Creatinine; Disease Progression; Female; Human | 2003 |
Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure.
Topics: Acrylates; Adult; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Drug Administration Sched | 2004 |
Adjunctive treatment with moxonidine versus nitrendipine for hypertensive patients with advanced renal failure: a cost-effectiveness analysis.
Topics: Antihypertensive Agents; Cost-Benefit Analysis; Disease Progression; Humans; Hypertension, Renal; Im | 2007 |
4 other studies available for moxonidine and Kidney Failure, Chronic
| Article | Year |
|---|---|
Modulation of gene expression by moxonidine in rats with chronic renal failure.
Topics: Animals; Biogenic Monoamines; Disease Progression; Gene Expression Regulation; Imidazoles; Kidney Fa | 2004 |
Effect of ramipril, nifedipine, and moxonidine on glomerular morphology and podocyte structure in experimental renal failure.
Topics: Animals; Antihypertensive Agents; Capillaries; Imidazoles; Kidney Failure, Chronic; Kidney Glomerulu | 1996 |
Arteriolar wall thickening, capillary rarefaction and interstitial fibrosis in the heart of rats with renal failure:the effects of ramipril, nifedipine and moxonidine.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Aorta, Thoracic; Arterio | 1996 |
The influence of renal function on clinical pharmacokinetics of moxonidine.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Female; Half-Life; Humans; Imidazoles; Kidney; | 1988 |